2. Academic Validation
  3. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

  • Invest New Drugs. 2017 Jun;35(3):397. doi: 10.1007/s10637-017-0455-y.
S Fu 1,  H Hirte 2,  S Welch 3,  T T Ilenchuk 4,  T Lutes 4,  C Rice 4,  N Fields 5,  A Nemet 6,  D Dugourd 4,  S Piha-Paul 1,  V Subbiah 1,  L Liu 1,  J Gong 1,  D Hong 1,  J M Stewart 7
Affiliations

Affiliations

  • 1 Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.
  • 2 Juravinski Cancer Centre, Hamilton, ON, Canada.
  • 3 London Health Sciences Centre, London, ON, Canada.
  • 4 Soricimed Biopharma Inc., Moncton, NB, Canada.
  • 5 Sagecon Inc., Oakville, ON, Canada.
  • 6 CLINSIG Research Consulting Inc., Brampton, ON, Canada.
  • 7 Soricimed Biopharma Inc., Moncton, NB, Canada. [email protected].
PMID: 28389981 DOI: 10.1007/s10637-017-0455-y
Figures
Products